What Limits the Physical Stability of Fluconazole Ophthalmic Suspensions?

Compounded ophthalmic preparations of fluconazole are commonly formulated at 2 mg/mL (0.2% w/v) in a sterile isotonic phosphate buffer, with the final pH adjusted between 5.5 and 6.5 to balance drug solubility, ocular tolerance, and chemical stability. The principal physical stability limitation is sedimentation in the microsuspension form, because fluconazole API as received often contains particles above the ophthalmic threshold. For suspension formulations, sterile milling or wet-micronisation is required to obtain a D90 below 10 µm; this particle-size ceiling is a direct safeguard against corneal abrasion and a release requirement aligned with USP 789. A viscosity modifier such as hypromellose E4M at 0.3–0.5% w/v may be incorporated to yield a measured viscosity from 8 mPa·s to 15 mPa·s at 25°C, which slows particle settling without producing blurring or lid crusting. Because fluconazole remains chemically stable under moist heat conditions, terminal steam sterilisation of the buffered drug solution at 121°C for 15 minutes can be used for solution presentations; suspension presentations require aseptic processing after sterilisation of the vehicle, typically inside an ISO 14644-1 Class 5 filling environment. Multidose ophthalmic configurations are tested for preservative effectiveness according to USP 51; if benzalkonium chloride is used at 0.01% w/v, preservative loss to membrane filters during cold sterilisation must be quantified, because adsorption onto mixed cellulose ester filters can reduce the free preservative concentration below the acceptance threshold.

Packaging for fluconazole ophthalmic suspensions shifts the release profile and must be assessed rather than assumed. Low-density polyethylene dropper bottles exhibit moisture vapour loss and may allow pH drift during room-temperature storage; glass bottles with silicone rubber dropper bulbs and nylon tips reduce evaporative loss but introduce extractable concerns under accelerated conditions of 40°C/75% RH as described in ICH Q1A(R2) stress protocols. In-use stability data for compounded fluconazole ophthalmic drops are frequently assigned a 28-day discard period at refrigerated temperature, but published data for this specific configuration is limited, and release beyond 14 days should be supported by sterility and preservative efficacy retesting rather than extension of textbook stability estimates.

Direct Compression of Fluconazole in Companion Animal Tablets

For companion animal tablet manufacturing, fluconazole is produced at three common label strengths: 50 mg, 100 mg, and 200 mg. Direct compression is used when the API is pre-milled to a D90 not exceeding 150 µm, because larger primary particles retard blend homogeneity and produce visible speckling in uncoated tablets. A typical dry blend comprises fluconazole at 40–60% w/w of core mass, microcrystalline cellulose PH102 as a compressible filler, croscarmellose sodium at 1.0–2.0% w/w as disintegrant, colloidal silicon dioxide at 0.5–1.0% w/w as glidant, and magnesium stearate at 0.25–0.75% w/w as lubricant. Lubrication time is constrained to 3–5 minutes in a bin blender at 25 rpm; prolonged mixing beyond 8 minutes produces hydrophobic magnesium stearate films that reduce tablet tensile strength and delay dissolution of the slow-dissolving triazole fraction. Compression on a rotary tablet press with a die table speed of 20–50 rpm and a main compression force of 5–15 kN yields cores with hardness between 5 kP and 8 kP and friability below 1.0% as measured by USP 1216. Blend uniformity is verified with stratified sampling across at least 10 locations and an RSD limit of 5.0% before compression; content uniformity of finished tablets follows USP 905, with an acceptance value not exceeding 15 across the strength range.

Dissolution is the primary release-rate control and is run using USP 711 Apparatus 2 at 50 rpm in 0.1 N hydrochloric acid at 37°C. Published pharmacopoeial dissolution specifications for fluconazole tablets commonly require not less than 80% release at 30 minutes. Film coating with hypromellose-based aqueous systems adds 2–3% w/w to the core mass and does not materially alter the dissolution profile if the coating pan exhaust temperature is kept below 60°C. Batches that fall below the release threshold on first testing are not salvageable by additional disintegration adjustment; the failure is usually traced to over-lubrication or excessive compaction pressure, and the batch is rejected rather than reworked under veterinary GMP expectations.

Fluconazole injectable solutions for veterinary use are compounded at 2 mg/mL in 0.9% w/v sodium chloride or Lactated Ringer’s Injection, with the pH adjusted by hydrochloric acid or sodium hydroxide to a final range of 4.0–6.5. The solution is filtered through a 0.45 µm prefilter followed by a 0.22 µm sterilising-grade membrane prior to filling, and the filled containers are terminally steam sterilised with an overkill cycle delivering an F0 of not less than 12 minutes at 121°C. Heat exposure at this process intensity does not significantly degrade fluconazole; solution clarity and assay are monitored after autoclaving as part of process validation. Container systems are Type I borosilicate glass vials with halobutyl rubber stoppers or polyolefin flexible bags; PVC containers are avoided where sorption or plasticiser migration may compete with the aqueous drug, although published fluconazole-specific sorption data is limited. Endotoxin burden is controlled by USP 85 with a limit derived from the intended dose and animal body-weight category, while subvisible particulates are quantified by light obscuration according to USP 788. Filled injectable solutions are held at controlled room temperature and protected from freezing; repeated freeze-thaw cycles have been associated with precipitation in compounded saline formulations, so distribution controls prohibit storage below 2°C unless forced degradation data support colder shipping windows.

For capsules, fluconazole API is dry-filled after geometric dilution with lactose monohydrate and microcrystalline cellulose in a low-shear tumble blender; environmental humidity is kept below 60% RH to prevent gelatin shell softening and powder clumping. Blend RSD before filling is controlled to 5.0% or less, and the filled shells are tested under USP 905 for weight variation and USP 701 for disintegration, with all units disintegrating within 15 minutes in water at 37°C.

When Fluconazole is Dry-Granulated for Sachet Reconstitution

Oral suspension sachets and reconstitutable powders are designed to deliver 10 mg/mL or 40 mg/mL after reconstitution in purified water, with the dry granule blend designed for rapid wetting and uniform dose withdrawal. Wet granulation is preferred over direct dry blending because fluconazole has poor flow and low bulk density; a high-shear granulator is charged with fluconazole, sucrose or sorbitol as a carrier, xanthan gum at 0.3% w/v in the final reconstituted volume, and povidone K30 at 1.0–2.0% w/w as binder. The granulation solvent is isopropanol or ethanol-water rather than plain water to limit fluconazole dissolution during kneading and to keep granule hardening under control. Drying is performed in a fluid-bed dryer with inlet air at 55–65°C and product temperature maintained at 35–40°C; the dried granule mass is milled through a 1.0 mm screen and the 150–500 µm sieve fraction is collected for sachet filling under 25% RH or lower. Residual solvent is reported against VICH GL18 limits, and loss on drying is held below 2.0% w/w before packaging. After reconstitution, the suspension pH is checked and adjusted to 4.0–6.5; viscosity is measured with a rotational viscometer and falls between 30 mPa·s and 50 mPa·s at 25°C, a band that maintains pourability while retarding caking. Dose uniformity after reconstitution is verified by withdrawing the first and final doses from a labelled bottle and comparing drug content using Ph. Eur. 2.9.5 principles; the between-dose difference should not exceed 5.0% relative standard deviation across 5 units.

Chemical stability of reconstituted fluconazole oral suspension is affected by preservative selection more than by the triazole degradation rate. Sodium benzoate at 0.1–0.2% w/v and potassium sorbate at 0.1% w/v are used in multidose presentations; the combination is assessed for preservative efficacy using USP 51 criteria. Storage after reconstitution is typically limited to 14 days at 2–8°C for non-sterile oral suspensions, but this is not an inherent fluconazole limit; it reflects the absence of robust challenge data for all possible water qualities and container closures. Sachet configurations that exclude preservatives require single-use reconstitution and immediate administration, with no post-use retention time assigned.

Because fluconazole premix inclusion in food-producing species lacks a harmonised approval pathway, practical premix use is restricted to non-food animal feeds in zoological collections, laboratory rodent diets, or research facilities where extemporaneous medicated feed is prepared under veterinary supervision. The API is sprayed as a suspended film onto inert carriers such as maltodextrin or calcium carbonate using a fluid-bed coater fitted with a Wurster insert; this process is selected to reduce segregation of the low-dust fluconazole fraction during screw auger or ribbon mixing. Homogeneity is monitored by HPLC assay on 10 stratified sampling points per batch, with a coefficient of variation below 5.0% before cargo release. Published data for this specific configuration is limited, and no uniform international premix concentration standard exists; inclusion rates must be calculated from individual animal doses and feed intake, not from a fixed commercial premix ratio.